findmyKOL

Eunice Wang, MD

Enriched profile

Chief, Department of Medicine – Leukemia; Professor of Oncology; Leukemia Clinical Disease Team Leader; Vice Chair, Academic Affairs, Department of Medicine · Roswell Park Comprehensive Cancer Center

ORCIDNPI
Region🇺🇸 Buffalo, NY · Northeast · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Eunice Wang is Chief, Department of Medicine – Leukemia; Professor of Oncology; Leukemia Clinical Disease Team Leader; Vice Chair, Academic Affairs, Department of Medicine at Roswell Park Comprehensive Cancer Center. OpenAlex indexes 738 publications with 16,565 citations (h-index 68); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Eunice S. Wang, MD, is Chief, Department of Medicine – Leukemia at Roswell Park Comprehensive Cancer Center, Buffalo, NY. The public record shows 738 publications with 16,565 citations (h-index 68), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 30 companies.

  • Most recent indexed publication: 2026 · Blood cancer journal
  • Top research focus: Acute Myeloid Leukemia Research
  • 16 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 30 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)14 trialsLeukemia, Myeloid, Acute13 trialsMDS / MPN7 trialsRecurrence2 trialsPrimary Myelofibrosis2 trialsPolycythemia Vera2 trialsThrombocythemia, Essential2 trialsThrombocytosis2 trialsPolycythemia2 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma2 trialsLeukemia, Erythroblastic, Acute1 trialMultiple Myeloma1 trialLymphoma1 trialBurkitt Lymphoma1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia researchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Xospatageneric · GilteritinibClinical trials1Industry payments16Publications2Onureggeneric · AzacitidineClinical trials1Industry payments5Publications9Venclextageneric · VenetoclaxClinical trials1Industry payments12Publications2

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trialsIndustry payments21Astellas Pharma US IncClinical trialsIndustry payments20Kite Pharma, Inc.Clinical trialsIndustry payments19

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
738publications

Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.

16,565citations

Total citations across indexed works.

68h-index

Hirsch index (OpenAlex). i10-index 239.

Clinical & industry

trials, payments and federal funding
16clinical trials

Investigator role on registered studies.

View trials
30companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Kinase inhibitor34.5%
    Jakafi100%
    Part D<11 patients
    Antimetabolite24.1%
    Hydroxyurea100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

222 congress contributions (2005–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Meir Wetzler133Elizabeth A. Griffiths128Richard M. Stone84

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/eunice-s-wang-md-68992221

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Eunice-Wang-3

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/md.education/p/C4dfmE_srdg

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com
  • Other

    onclive.com/authors/eunice-wang-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com
  • X / Twitter

    x.com/BloodCancerUtd/status/1231573176582365185

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Hematology (2004), American Board of Internal Medicine

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org
  • Board Certified

    Medical Oncology (2002), American Board of Internal Medicine

    2002
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org
  • Hematology-Oncology Fellowship

    Memorial Sloan Kettering Cancer Center

    2002
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org
  • Board Certified

    Internal Medicine (1999), American Board of Internal Medicine

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org
  • Internal Medicine Residency

    Yale-New Haven Hospital

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org
  • MD

    Keck School of Medicine, University of Southern California

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.buffalo.edu
  • AB

    Biological Sciences, Harvard-Radcliffe Colleges, Harvard University, Cum Laude

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.buffalo.edu

Editorial & leadership roles

journal and society appointments
  • Associate Editor

    Leukemia Research Reports

    2012
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.buffalo.edu
  • Member

    National Comprehensive Cancer Network (NCCN) Acute Myeloid Leukemia Guidelines Panel

    2008
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.buffalo.edu
  • Member

    American Society of Clinical Oncology

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.buffalo.edu
3 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Associate Professor

    Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (SUNY)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.buffalo.edu
  • Assistant Member

    Tumor Immunology Program, Roswell Park

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org

Media & interviews

press, podcasts and appearances
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.